•Cellution Biologics debuts ocular surface amniotic graft•FDA clears Balance Ophthalmics' wireless-enabled IOP device for glaucoma•Do anti-VEGF injections increase cataract risk?•Real-world TED data finds disease advances beyond acute phase•FDA agrees to special protocol assessment for Oculis’s phase 3 ON trial•Cellution Biologics debuts ocular surface amniotic graft•FDA clears Balance Ophthalmics' wireless-enabled IOP device for glaucoma•Do anti-VEGF injections increase cataract risk?•Real-world TED data finds disease advances beyond acute phase•FDA agrees to special protocol assessment for Oculis’s phase 3 ON trial
HEADLINES
FEATURED
After 6 weeks, patients experienced an average of 71% reduction in DES symptoms and three-fourths reported no end-of-day fatigue.
Earn FREE CE 24/7 with Courses by Eyes On Eyecare
Explore premium-quality, bite-sized courses featuring leading experts like Cecelia Koetting, OD, FAAO, and Cory Lappin, OD, MS, FAAO, and continuing education covering topics from ocular rosacea treatments to retinal disease.
